Oncology

Drug found to slow cyst growth in patients with autosomal dominant polycystic kidney disease.

Determining how hepatitis C progresses is important when considering therapies and the associated costs for different patient groups.

Bruce A. Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, discusses the key elements of an effective cancer clinical care pathways program.

Top news of the day from across the healthcare landscape.

The Department of Veterans Affairs and Bristol-Myers Squibb Foundation seek to increase lung cancer screening among veterans.

Allowing patients to control mammography compression may improve stress associated with breast cancer screening.

Patients with breast cancer who are more rational may strongly consider contralateral mastectomy.

Up to 1.3 million women may not be receiving genetic testing to detect BRCA 1/2 mutations, which increase the risk of certain cancer types.

Self-administered acupressure found to improve sleep and daytime alertness among breast cancer survivors.

The findings highlight the role of Tregs in suppressing the immune response.

Targeting the arginase 2 enzyme observed to reduce the growth of pancreatic cancer.

Tisagenlecleucel (Kymriah) is a personalized genetically-modified autologous T cell immunotherapy designed to use a patient’s own T cells to target and kill leukemia.

Tisagenlecleucel is indicated for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia.

Statins may provide a protective effect against breast cancer development.

Epigenetic drugs may reduce viral reactivation of herpes and other viruses.

Scientists hone in on personalized treatments for patients with cancer.

Top news of the day from across the health care landscape.

An estimated 1.2 million American women would likely benefit from recommended genetic test to assess their risk of cancer.

The risk of developing liver cancer is similar with direct-acting antiviral drugs or interferon therapy for hepatitis C virus.

Alcohol consumption results in more than $150 million spent on breast cancer annually.

FDA to evaluate obinutuzumab (Gazyva) in combination with chemotherapy for patients with previously untreated follicular lymphoma.

Experimental drug shows evidence of lowering cholesterol, reducing risk of cardiovascular disease, and potentially treating lung cancer.

Fulvestrant is a hormonal therapy that targets the estrogen receptor and helps slow cancer growth.

Faslodex reduced disease progression by 20% among women with HR+, HER2- advanced breast cancer.

A drug being explored as a cardiovascular disease treatment may also reduce the risk of lung cancer.

A decision on the approval of obinutuzumab is expected by December 23, 2017.

Top news of the day from across the health care landscape.

Hormone therapy is recommended to treat menopause symptoms, but is not recommended for breast cancer survivors.